The purpose of this commissioning framework is to support integrated care boards (ICBs) as commissioners of COVID-19 therapeutics for non-hospitalised patients who will benefit from them the most. This framework is intended to assist ICBs in establishing and maintaining timely access to COVID-19 therapeutics during the remainder of 2022/23 in preparation for routine provision from April 2023.